|1.||McCollum, Gary W: 1 article (01/2015)|
|2.||Yang, Rong: 1 article (01/2015)|
|3.||Savage, Sara R: 1 article (01/2015)|
|4.||Penn, John S: 1 article (01/2015)|
|5.||Zhang, Shi: 1 article (04/2014)|
|6.||Fang, Yi-Qun: 1 article (04/2014)|
|7.||Ma, Jun: 1 article (04/2014)|
|8.||You, Pu: 1 article (04/2014)|
|9.||Bao, Xiao-Chen: 1 article (04/2014)|
|10.||Chen, Sheng-Hsien: 1 article (01/2014)|
04/01/2014 - "The results indicated that after HBO2 exposure, the lung injury was obviously decreased in the nNOS(-/-)+GSK0660 mice compared to the wild-type +GSK0660 mice; furthermore, administration of GSK0660 significantly elevated the lung injury in the eNOS(-/-) mice. "
04/01/2014 - "Treatment of rats with GSK0660 exacerbated lung injury and elevated the levels of nNOS and eNOS in the lungs. "
04/01/2014 - "In this study, we used GW0742, a PPAR-β/δ agonist, and GSK0660, a PPAR-β/δ antagonist, to test the role of PPAR-β/δ in lung injury due to hyperbaric oxygen (HBO2) exposure. "
01/01/2015 - "We used RNA-seq to better understand the role of the antagonist and inverse agonist of PPARβ/δ, GSK0660, in TNFα-induced inflammation. "
01/01/2015 - "Understanding the underlying mechanisms of vascular inflammation could lead to new treatments for DR. RNA was isolated from human retinal microvascular endothelial cells treated with a vehicle, TNFα, or TNFα plus GSK0660. "
05/01/2013 - "However, co-administration of GSK0660 (0.3 mg/kg/i.p/4 days) along with both ATRA (5 mg/kg/p.o/4 days) and GW0742 (0.1 mg/kg/i.p/4 days), significantly reverse the decreased paw edema, MH, and TH. "
05/01/2013 - "Administration of GSK0660, selective PPAR-β/δ receptor antagonist, at a dose of (0.3 mg/kg/i.p/4 days), did not produce a significant effect on carrageenan-induced paw edema, MH and TH. "
|1.||Peroxisome Proliferator-Activated Receptors (PPAR)
|5.||RNA (Ribonucleic Acid)